RE:RE:RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsEmerging data suggest that mechanisms of resistance to ADCs may be linked to both the choice of target and the characteristics of the payload. Notably, the full extent of the effects of the payloads, though substantial, remains incompletely characterized because while the payload facilitates the homing effect of the ADC toward the tumor and detaches itself from the antibody while circulating in the bloodstream, this detachment contributes to a sustained release of chemotherapy This slow release of the chemotherapy payload lends to the inefficacy of the ADC within the tumor microenvironment, and due to the lack of diversify of the payload, narrow activity throughout the bloodstream results, more particularly in heterogeneous tumors, like breast cancer, and the consequence is that ADC resistance develops in short order.